
    
      Selective photocoagulation is the standard treatment for clinically significant macular
      edema. This treatment decreased the incidence of moderate visual loss in the long term.
      Nonetheless, in the first six weeks after treatment it is induced, probably because an
      exacerbation of macular edema secondary to treatment. An inflammatory response has been
      reported after selective photocoagulation. Therefore, antiinflammatory therapy like ketorolac
      or nepafenac could be useful to manage center point thickness secondary to selective
      photocoagulation in diabetics with macular edema.
    
  